Abnormalities in purine availability or purinergic receptor density are commonly seen in patients with lower urinary tract symptoms (LUTS), but the underlying mechanisms relating altered receptor function to LUTS are unknown. Here we provide extensive evidence for the reciprocal interplay of multiple receptors responding to ATP, ADP (adenosine diphosphate), and adenosine, agonists that regulate bladder function significantly. ADP stimulated P2Y 12 receptors, causing bladder smooth muscle (BSM) contraction, whereas adenosine signaling through potentially newly defined A2b receptors, actively inhibited BSM purinergic contractility. The modulation of adenylyl cyclase-cAMP signaling via A2b and P2Y 12 interaction actively regulated bladder contractility by modulating intracellular calcium levels. KO mice lacking the receptors display diametrically opposed bladder phenotypes, with P2Y 12 -KO mice exhibiting an underactive bladder (UAB) phenotype with increased bladder capacity and reduced voiding frequency, whereas A2b-KO mice have an overactive bladder (OAB), with decreased capacity and increased voiding frequency. The opposing phenotypes in P2Y 12 -KO and A2b-KO mice not only resulted from dysregulated BSM contractility, but also from abnormal BSM cell growth. Finally, we demonstrate that i.p. administration of drugs targeting P2Y 12 or A2b receptor rescues these abnormal phenotypes in both KO mice. These findings strongly indicate that P2Y 12 and A2b receptors are attractive therapeutic targets for human patients with LUTS.
Introduction
Lower urinary tract symptoms (LUTS) constitute a group of urinary disorders that are highly prevalent and affect more than half of the population aged older than 40 years (1, 2) . Current drugs for LUTS include antimuscarinics and a recent FDA-approved agonist targeting adrenergic β 3 receptors in bladder smooth muscle (BSM). Because these drugs have limited efficacy and high rates of adverse effects, they are often discontinued by patients (3) (4) (5) . For example, oxybutynin, an antimuscarinic drug targeted to treat bladder overactivity (OAB), shows marginal beneficial effects of only 13%-25% over placebo (5) , and a study in rats indicated that chronic administration of oxybutynin induced a shift from muscarinic to purinergic transmission in the bladder wall. This finding, if also true in humans, indicates a likely reduction in antimuscarinic efficacy with prolonged treatment (6) . Therefore, there is a clear need to identify new pathways and better targets for treating LUTS.
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contraction force, respectively (10, 11) . In addition, externally applied α,β-meATP (as opposed to EFSstimulated neuronal release) elicited significant human BSM contraction, and P2X 1 receptor is highly expressed in human BSM (12, 13) . In pathological conditions, contraction in response to neuromuscular purinergic signaling can account for up to 65% of total force in patients with OAB, partial bladder outlet obstruction, and diabetic bladder dysfunction (14) (15) (16) (17) (18) (19) . A common finding in these patients is elevated ATP release and/or altered P2X receptor expression. Finally, the importance of purinergic signaling in regulating bladder function is further confirmed by recent findings from 2 human patients with loss-of-function mutations in ENTPD1, an ectonucleotidase enzyme that converts ATP to ADP and ADP to AMP (20) . These patients display bladder hypomotility and incontinence (Alexander Lossos, personal communication).
Intriguingly, bladder myocytes express ENTPD1 and ecto-5′-nucleotidase (NT5E) on their cell surface (21) , meaning that ATP is eventually converted into ADP and ultimately adenosine by these enzymes. Both compounds have been shown to have bioeffector functions on BSM. ADP was reported to be a potent agonist for inducing BSM contraction, and ADPβS (an analog of ADP) was found to be as potent as P2X 1 receptor agonist α,β-meATP in inducing human BSM contraction (12, 22, 23) . Using pharmacological tools, we recently demonstrated that ADP-induced bladder contractility is mediated by P2Y 12 receptor and that contraction was temporally regulated by ectonucleotidases and adenosine signaling (24) . Adenosine, which originated from the conversion of ADP by Nt5E, was reported to relax BSM by activating adenosine A2 receptors. Both A2a and A2b have been suggested as being expressed in BSM for bladder relaxation (25) (26) (27) (28) ; however, the exact adenosine receptor subtypes and how they are involved in modulating bladder activity has remained unclear.
It thus appears that all the necessary machinery exists for ATP and its downstream metabolites, ADP and adenosine, to play an important functional role in regulating bladder activity. In addition, the purinergic receptors mediating the effects of these signaling molecules could be druggable targets for treating bladder dysfunctions. However, how these molecules and receptors regulate contraction and relaxation, and whether these signaling cascades have coordinated interplay, remains unknown. To answer these questions, we have investigated in vivo and in vitro bladder function in both P2Y 12 and A2b receptor-KO mice. Our data indicate that these receptors signal in opposing directions through modulation of adenylyl cyclase and cyclic AMP (AC-cAMP) pathway in a way that has effects on calcium signaling. Notably, in vivo administration of compounds that target these 2 receptors rescues phenotypic abnormalities in both models.
Results

Activation of adenosine A2 receptors predominantly inhibits purinergic, but not muscarinic, BSM contraction.
Adenosine or adenosine receptor agonists are known to relax BSM contraction through the activation of A2 receptors. To explore the underlying mechanism, we tested this effect by using a nonselective adenosine agonist NECA in mucosa-dissected mouse BSM strips. Myography indicates that NECA significantly inhibited EFS-induced BSM contraction, especially at low-frequency EFS stimulation, which abolished most of the force ( Figure 1A , left-hand contraction spikes). However, NECA did not inhibit BSM contraction completely, which was evident at higher frequency EFS stimulation ( Figure 1A , righthand spikes), in which approximately 60% of the force remains even at high doses.
It has been suggested that BSM purinergic contractility is sensitive to low-frequency EFS stimulation which functions to initiate BSM contraction, whereas BSM muscarinic contractility is sensitive to high-frequency EFS stimulation, which functions to produce sustained BSM contraction to expel urine (8) . Based on results seen in Figure 1A , in which the degree of inhibition was dependent on electrical field frequency, we hypothesized that NECA might predominantly inhibit BSM purinergic contractility. To test this hypothesis, we pretreated the BSM with 0.5 μM atropine, which abolished the muscarinic contractility and spared purinergic contractility. In this condition, further treatment of BSM with NECA completely inhibited BSM contractility with an IC 50 of approximately 0.53 μM (Figure 1 , B, D, and E), supporting our hypothesis. Conversely, pretreatment of BSM with α,β-meATP, which desensitizes a major BSM purinergic receptor P2X 1 , revealed that α,β-meATP-resistant force was largely insensitive to NECA (Figure 1 , C and E) but could be completely abolished by further atropine treatment (data not shown). These data clearly indicate that adenosine receptor activation in BSM by NECA predominantly inhibits BSM contraction driven by purinergic agonists (we define this as purinergic contraction). We further tested whether activation of adenosine receptor inhibits ADP-mediated BSM contraction. NECA dose-dependently abolished ADPβS-elicited BSM contraction (Figure 1, F and G) , suggesting there is elaborate interplay among ATP, ADP, and adenosine-mediated signaling in regulating bladder contractility. A2b is the major adenosine receptor mediating inhibition of BSM purinergic contraction. To determine which A2 receptor mediates purinergic inhibition, we tested the effect of potent A2a-and A2b-selective receptor agonists, CGS21680 and Bay 60-6583, respectively. At concentrations known to inhibit selectively A2b receptors, Bay 60-6583 dose-dependently inhibits EFS-induced BSM contraction. The observed IC 50 of approximately 1.76 nM and near-complete inhibition of BSM purinergic contraction force at approximately 50 nM were consistent with its reported IC 50 (Figure 2 , B and G). Conversely, CGS21680 exhibited little effect, even at dosages much higher than its IC 50 (Figure 2 , A and G), suggesting that A2b is the major receptor inhibiting purinergic contraction.
In further support of our hypothesis, CGS21680 and Bay 60-6583 were tested for their ability to inhibit ATP and ADP-mediated contraction pathways induced by α,β-meATP (mediated by P2X 1 ) and ADPβS (mediated by P2Y 12 ). As seen in Figure 2 , C-F, Bay 60-6583 potently inhibited contraction by these 2 agonists whereas the A2a agonist CGS21680 had no effect (Figure 2, C-F, H, I ). Finally, the dominant role of A2b receptor was further confirmed by A2b-KO mice, in which Bay 60-6583 failed to inhibit BSM purinergic contraction (Figure 2 , J-L).
Genetic deletion of A2b or P2Y 12 receptor results in altered conscious voiding patterns and urodynamic parameters. To understand the in vivo function of A2b receptor and P2Y 12 receptor-mediated signaling, P2Y 12 -KO and A2b-KO mice were examined. Deletion of P2Y 12 and A2b genes were verified by genomic DNA genotyping (Supplemental Figure 1 , A and C; supplemental material available online with this article; https://doi. org/10.1172/jci.insight.122112DS1) and mRNA expression analysis (Supplemental Figure 1 , B and D). A2b gene KO was further determined using X-gal staining, with which β-gal (knocked into A2b-KO mice) can be visualized in blue (Supplemental Figure 1E) .
Interestingly, deletion of P2Y 12 resulted in a significantly heavier bladder. In direct contrast, deletion of A2b resulted in a significantly smaller and lighter bladder (Table 1) . To evaluate conscious spontaneous bladder function in these KO mice, quantitative voiding spot assays (VSAs) were performed in female mice. As shown in Figure 3 , A-F, normal wild-type mice produced approximately 3.80 primary voiding spots (PVSs) of 346 mm 2 mean area in a 4-hour period. Deletion of P2Y 12 , however, resulted in significantly larger PVSs but there were fewer of them, whereas deletion of A2b caused significantly smaller spots with increased numbers of individual voids ( Figure 3 , A-F). Because of the potential differences of purinergic signaling in male and female mice bladders, VSAs were also performed in male P2Y 12 and A2b KO mice. Consistently, similar phenotypes were observed (Supplemental Figure 2) . Thus, deletion of P2Y 12 resulted in reduced voiding frequency and large bladder capacity, and deletion of A2b receptor created the opposite phenotype with increased voiding frequency and a smaller bladder capacity.
Bladder urodynamic function of P2Y 12 -KO and A2b-KO mice was next characterized by cystometrogram (CMG) in female mice. Figure 3 , G-I, shows CMG traces in which time-dependent bladder pressure changes are recorded during continuous filling and emptying cycles, from wild-type mice and both KO models. Intrabladder pressure profiles were dramatically different between models, with P2Y 12 -KO mice having much longer intercontractile (voiding) intervals than wild-type mice, whereas compliance was greater and micturition pressures (i.e., peak pressure) were higher ( Figure 3 , J-N). Diametrically opposed to this, the A2b-KO mice exhibited significantly shorter intercontractile intervals, reduced bladder compliance, and lower micturition pressures than wild-type mice ( Figure 3 , J-N). Basal pressure and threshold pressure (for voiding) were not different, suggesting that there was no afferent sensory defect in the KO mice. These altered urodynamics are fully consistent with the bladder morphology and VSA data and, in sum, indicate that P2Y 12 -KO mice have a UAB phenotype, whereas the A2b-KO mice exhibit an OAB phenotype. Collectively, these observations suggest critical roles for P2Y 12 and A2b signaling in regulating bladder activity and further indicate the importance of extracellular ATP, ADP, and adenosine kinetics for bladder smooth muscle function.
Deletion of A2b or P2Y 12 receptor affects BSM contraction force in opposing directions. To determine whether loss of these receptors affects BSM contractility, which might explain the bladder phenotypes observed previously, we performed myography on isolated BSM strips. As shown in Figure 4A , normal BSM contractile force increased with increasing of EFS frequency, and average maximum force reaches approximately 30 mN. Deletion of P2Y 12 resulted in BSM that contracts more strongly, with the maximum force approaching 50 mN. In contrast, deletion of A2b receptor significantly reduces BSM contractile force, with maximum force only reaching approximately 20 mN (Figure 4 , A-D). By pretreating BSM tissue with atropine to block muscarinic contractile force, we investigated whether deletion of A2b or P2Y 12 affects the purinergic force component ( Figure 4E ). In this setting, deletion of P2Y 12 did not change the purinergic force percentage significantly; however, in A2b-deleted mice BSM, the purinergic force component increased significantly at the highest frequencies ( Figure 4E ).
AC-cAMP signaling cascade is critical in regulating BSM purinergic contractility through modulation of downstream Ca
2+ signaling. P2Y 12 and A2b receptors are both G protein-coupled receptors. P2Y 12 is coupled to G i , which inhibits adenylyl cyclase (AC) activity and thus decreases intracellular secondary messenger, cyclic AMP (cAMP). In contrast, A2b is coupled to G S , which stimulates AC activity and increases cAMP. Logically, it appears that interplay between P2Y 12 and A2b receptors by modulating downstream AC-cAMP signaling is critical in regulating BSM purinergic contractility; this finding also explains the opposing bladder activities (VSA, CMG) and BSM contractility observed in P2Y 12 -KO and A2b-KO mice.
To test whether BSM purinergic contractility is sensitive to AC-cAMP signaling, BSM was pretreated with AC activators forskolin and NKH 477 before EFS stimulation. Both forskolin and NKH 477 dose-dependently inhibited BSM purinergic contractile force (Figure 4 , F-J). These data strongly suggest that AC-cAMP signaling plays a critical role in mediating the opposing effects generated by ADP and adenosine signaling via P2Y 12 and A2b, respectively.
Activation of P2X1 by ATP can stimulate BSM purinergic contraction by ryanodine receptor-mediated Ca 2+ release (9) , and our data indicate that P2Y 12 or A2b activation regulates BSM purinergic contractility by modulating AC-cAMP signaling. Thus, we hypothesized that AC-cAMP signaling could affect purinergic contractility through modulating downstream Ca 2+ signaling. To test this hypothesis, primary cultured mouse BSM cells were used for Ca 2+ imaging. As shown in Figure 5 , ATP and ADPβS were applied to activate BSM P2X 1 and P2Y 12 receptors, which increased intracellular Ca 2+ signaling significantly. However, when cells were pretreated with A2b receptor agonist Bay 60-6583, the ATP and ADPβS-induced BSM intracellular Ca 2+ signaling was dramatically inhibited. ATP and ADPβS-induced BSM intracellular Ca 2+ signaling was also inhibited by AC-cAMP activator forskolin, again indicating that BSM purinergic contractility is regulated by AC-cAMP signaling ( Figure 5 , A-H). To ascertain whether these signaling pathways are also present in the human bladder, parallel studies were performed in primary cultured human BSM cells. Consistent with the mouse data, our results in human cells indicate that ATP and ADPβS both induce significant calcium influx, which is inhibited by A2b receptor agonist Bay 60-6583 and AC-cAMP activator forskolin ( Figure 5 , I-L). In sum, these data strongly suggest the importance of the interplay of these receptors in regulating BSM function not just in mice, but also in humans, and suggest a conserved pathway in both species. P2Y 12 and A2b signaling modulate BSM cell growth differentially. In addition to the acute effects on BSM contractility, AC-cAMP signaling is also an important pathway in regulating cellular proliferation and differentiation by phosphorylating transcription factors, such as cyclic AMP response element (CREB) (29) (30) (31) (32) . CREB can further upregulate downstream immediate early genes (IEGs), which provide important links by which extracellular signals regulate gene transcription (33) . IEGs are rapidly inducible effectors playing critical roles in regulating cellular function by regulating expression of other genes, thus modulating cell survival and plasticity, proliferation, and differentiation. c-fos and c-jun are the most extensively characterized IEGs and are sometimes described as third messengers because of their critical importance in gene regulation (34) . c-fos and c-jun are upregulated in neuronal cells in response to Cav1.2 activation (35) (36) (37) (38) and in smooth muscle cells in response to mechanical stretch (39) . As noted previously (Table 1) , deletion of P2Y 12 results in a significantly larger bladder whereas deletion of A2b causes a smaller bladder. The difference is visually obvious (Figure 6 , A-E), implying that deletion of P2Y 12 or A2b affect BSM proliferation or differentiation because of altered AC-cAMP signaling. To test whether deletion of P2Y 12 or A2b affects cell proliferation, sections were immunolabeled with anti-Ki67 antibody and images were quantified. The data indicated no detectable difference in the number of Ki-67 + nuclei among wild-type, P2Y 12 -, and A2b-deleted mice bladders ( Figure 6 , F-I, and Supplemental Figure 3) . Interestingly, however, BSM cell size appeared to be substantially larger in P2Y 12 -deleted bladders and smaller in A2b-deleted bladders ( Figure 6 , N and O, compared with Figure 6M ). To quantitate these apparent differences, we were confronted with the problem that myocytes in any image field may be in longitudinal or transverse orientations. In addition, because they are elongated, the cross-sectional area can vary greatly depending on the position of the optical sectioning. As a result, we developed a method (shown schematically in Figure 6P ) by which we only quantitated cells we viewed in cross-section (dotted rectangle) and which contained DAPI-stained nuclei. This ensured comparability of the subcellular region of similarly aligned cells for quantitative purposes. The analysis revealed that P2Y 12 -KO myocytes were bigger than wild-type myocytes, whereas the A2bs were smaller ( Figure 6Q ), suggesting that deletion of P2Y 12 or A2b affects BSM cell differentiation or growth through aberrant AC-cAMP signaling. Indeed, c-fos and c-jun were upregulated significantly at both the mRNA and protein level in P2Y 12 -deleted mice bladders, consistent with the larger BSM cell size and heavier bladder in P2Y 12 -deleted mice ( Figure 6 , R-V). To investigate whether Hippo pathway (an important signaling cascade for controlling organ size) is involved in the BSM cell size difference, critical Hippo pathway genes were analyzed using quantitative RT-PCR. The data showed marginal increases in some mRNAs from P2Y 12 -KO BSM tissue compared with wild-type control, suggesting in sum, the likelihood of no involvement of this pathway (Supplemental Table 1 ).
In further efforts to examine the molecular mechanisms underlying the significant difference in contractile forces in P2Y 12 -and A2b-deficient bladders, we determined the expression of P2X 1 and Cav1.2 at both mRNA and protein levels. P2X 1 initiates bladder contraction, and P2Y 12 and A2b signaling can modulate its contractility. Cav1.2 is an essential gene for BSM and the final executor for BSM contraction via Ca 2+ influx, which directly determines the contraction force of BSM (40) . Both P2X 1 and Cav1.2 are expressed at normal levels, despite the changes of contractile force in P2Y 12 -and A2b-deleted mice (Supplemental Figures 4  and 5) . We also determined expression of sm22α, a smooth muscle differentiation marker. Again, no detectable change can be observed in either P2Y 12 -KO and A2b-KO mice (Supplemental Figures 4 and 5) . However, P2Y 12 was significantly increased in A2b-deleted mouse bladder, whereas A2b was significantly increased in P2Y 12 -deleted mouse bladder, confirming pathway cross-talk in modulating bladder contractility and revealed for the first time in these 2 complementary models. 12 -KO (n = 12), and A2b-KO (n = 16) mice, respectively, which are quantitated in D. Data are shown as box and whiskers, whiskers are from minimum to maximum, Student's t test is used to compare between wild-type and KO animals; *P < 0.05. (E) Bladder strips exposed to atropine first were tested by EFS and the remaining purinergic force component is shown. (F and G) Representative traces of BSM purinergic contraction in response to EFS stimulation, which can be fully inhibited by adenylyl cyclase activators forskolin (n = 7) and NKH477 (n = 8), respectively. (H and I) Summarized data for F and G, respectively. (J) Dose response analyzed by nonlinear regression and IC 50 .
suggesting that it might also increase water reabsorption in the kidney collecting duct and reduce the production of urine, an effect that could be particularly beneficial for patients with frequency and nocturia. To test this hypothesis, urine samples were collected and subjected to osmolality and chemical analysis. Interestingly, administration of Bay 60-6583 (2 mg/kg) resulted in a significant increase in urine osmolality (about 2-fold), consistent with reduced urine volume and in support of increased water reabsorption (Supplemental Figure 6B) . Further chemical analysis indicated that urea concentration was significantly increased in urine from Bay 60-6583-treated mice (Supplemental Figure 6J ). We were curious about whether this phenomenon also existed in P2Y 12 -and A2b-deficient mice, and our data revealed some changes of osmolality and chemistry in these KO mice (Supplemental Figure 6) , but further refined studies are needed to clearly understand their role in the regulation of kidney function. 12 -KO (n = 6), and A2b-KO (n = 6) mice, which are quantitated by densitometry and normalized to β-actin in U and V. Data are shown as box and whiskers, whiskers are from minimum to maximum, Student's t test is used to compare between wild-type and KO animals; *P < 0.05.
As we noted above, deletion of P2Y 12 results in an UAB-like phenotype, and deletion of A2b causes an OAB-like phenotype; therefore, these KO mice themselves are strong models of OAB and UAB and will be useful for evaluating P2Y 12 and A2b receptors as drug targets for treating bladder disorders. In P2Y 12 -KO mouse bladder, because of the lack of P2Y 12 -mediated inhibition on AC-cAMP signaling, the A2b-mediated activation of AC-cAMP relaxation signaling will dominate (Figure 8) . Therefore, to test whether we could rescue the UAB phenotype in P2Y 12 -KO mice, we tested an A2b-receptor antagonist, PSB1115, by i.p. injections. Gratifyingly, PSB1115 dose-dependently reduced the size of PVSs and increased the number of PVSs in P2Y 12 -KO mice by VSAs (Figure 7, F-J) .
In the A2b-KO mouse, P2Y 12 -mediated contraction signaling dominates (Figure 8 ). Therefore, we were highly motivated to test whether the OAB phenotype in these mice could be rescued pharmacologically, particularly because FDA-approved drugs for this receptor are available. Ticagrelor is a reversible P2Y 12 antagonist that was approved by the FDA in 2011 for prevention of thrombotic events in patients with acute coronary syndrome or myocardial infarction. Intriguingly, mice given i.p. injections of Ticagrelor dose-dependently increased the volume of their voids while simultaneously urinating less frequently ( Figure 7, K-O) . In sum, these data strongly indicate that targeted manipulation of smooth muscle contraction and relaxation by modulating the interplay of the P2Y 12 and A2b pathway can correct common LUTS-like symptoms.
Discussion
Purinergic or ATP-induced bladder contractility has been known for almost 50 years, and BSM was the very first tissue in which the concept of purinergic signaling was developed (41, 42) . ATP is classically considered to exert its effects through P2X 1 receptors (8, 41, 42) . Operating in parallel to the muscarinic receptor-dependent pathway, purinergic signaling plays an important role in initiating voiding function. However, this framework captures only a small part of the overall picture and says nothing about how bladder muscle relaxes and how it is regulated. In our previous work and in this study, we defined functional purinergic receptors P2Y 12 and A2b in BSM. We have shown that BSM purinergic contractility is defined mainly by the interplay of P2X 1 , P2Y 12 , and A2b-mediated pathways acting antagonistically through AC-cAMP regulated Ca 2+ signaling (Figure 8) . We have clearly shown that P2Y 12 and A2b receptors are important regulators of bladder activities, and deletion of P2Y 12 or A2b receptors result in opposing effects (UAB-or OAB-like phenotypes, respectively). We have thus extended our understanding greatly on how bladder muscle is regulated by purinergic signaling. These findings are important not just for understanding normal physiology of this tissue but they also offer potentially new therapeutic approaches to bladder dysfunctions, in which it is worth noting that upregulated purinergic signaling is commonly observed. As mentioned previously, antimuscarinic approaches show only marginal benefits in treating OAB (5), and chronic administration of oxybutynin induces a shift from muscarinic to purinergic transmission in the bladder wall of rats (6) . Thus, drugs targeting this purinergic pathway will be of particular relevance in treating bladder dysfunctions. Our findings indicate that the opposing interplay of these receptors is predominantly restricted to effects on purinergic contractility and has little or no effect on muscarinic contractility. For example, A2b activation predominantly inhibits purinergic contraction induced by P2X 1 and P2Y 12 signaling. This finding is noteworthy because purinergic contractility is believed to be important in initiating voiding, whereas muscarinic contractility is important to maintain sustained contraction to expel the urine. We can therefore expect that drugs that inhibit purinergic contractility by A2b activation or P2Y 12 antagonism will likely delay voiding initiation and increase the urine volume, as was shown in our KO mice and drug treatment studies in mice (Figures 3 and 7) . Conversely, because it does not interfere with muscarinic contractility directly, we can anticipate that the urine will be expelled completely, thus avoiding urine retention problems (and constipation, etc.) which are common adverse effects for antimuscarinics or β 3 receptor agonists.
We have shown that pharmacological activation of the P2Y 12 receptor causes significant BSM contraction, whereas activation of the A2b receptor inhibits BSM purinergic contraction. Therefore, it might be expected that deletion of the P2Y 12 receptor should result in reduced purinergic contractility and overall bladder contractile force and deletion of the A2b receptor should increase purinergic contraction and overall bladder contractile force. However, in vivo CMGs (Figure 3 ) and BSM strip experiments in KO mice show the opposite. Deletion of the P2Y 12 receptor results in significantly larger BSM contractile force and deletion of the A2b receptor causes diminished contractile force (Figure 4 ). This seems counterintuitive; however, according to length-tension theory in muscle physiology, muscle needs to be elongated to an optimal length to generate maximal contractile force. Our data therefore suggest that activation of P2Y 12 signaling increases muscle tension and thus reduces muscle elongation, whereas activation of A2b signaling relaxes muscle and thus increases muscle length, resulting in paradoxical force outcomes. In P2Y 12 -deleted mice (in which A2b signaling dominates, Figure 8 ), the muscle contractile force is significantly larger and the bladder capacity is also much bigger. The bladder is also more compliant with significantly higher peak pressures (Figures 3 and 4) . However, in A2b-deleted mice (in which P2Y 12 signaling dominates, Figure 8 ), all parameters are the opposite (Figures 3 and 4) .
Importantly, these data argue against the commonly held belief in urology that OAB is the result of too much contractile force, and thus drugs to treat OAB need to inhibit BSM contractile force. According to our findings, this dogma is overly simplistic because much more complicated mechanisms are at play (via length-tension optimization as a result of relaxation stimuli) in regulating bladder activity. In a CMG tracing, this could be colloquially summarized as "longer and stronger." Factors that increase BSM contractile force can actually result in increased bladder capacity and reduced bladder activity, whereas factors that decrease BSM contractile force can actually result in decreased capacity and overactivity as we have shown.
Deletion of the P2Y 12 or A2b receptor also results in significant remodeling of BSM. Our data indicate that proliferation seems unchanged in these bladders; however, intriguingly, there were significant differences in cell sizes ( Figure 6 ). This altered cellular morphology could also play a role in our observed phenotypes. First, it could physically enlarge and reduce bladder size in P2Y 12 -KO and A2b-KO mice, respectively, thus resulting in different bladder capacities in these KO mice. In addition, the larger BSM cells would presumably elongate further, perhaps resulting in greater capacity and higher contractile forces. The cell size difference is likely the result of different levels of cell growth. This is supported by our observation of changes in transcription factors c-fos and c-jun in P2Y 12 -or A2b-deleted mice bladders. Because the bladder receives stretch force physiologically and pathologically, which can both induce substantial ATP/ADP/ADO release, these purinergic signals might play an important role in bladder remodeling that is commonly seen in bladder dysfunctions. Purinergic dysfunction is a common phenomenon in human bladder diseases; elevated ATP release, impaired ATP hydrolysis, and dysregulated P2X expression have all been reported in patients with OAB, interstitial cystitis, and outlet obstruction (16) (17) (18) (43) (44) (45) (46) (47) (48) (49) (50) . The role of P2Y 12 and A2b receptors in human bladder function is not well known. However, both P2Y 12 and A2B mRNA are well expressed in human bladder according to NCBI data. Interestingly, ADPβS has long been known to induce significant human BSM contraction, suggesting an important role of the P2Y 12 receptor in regulating human bladder activity (12, (22) (23) (24) . Likewise, Northern blot and quantitative PCR analyses suggest high expression of A2b receptors in the human bladder wall (51, 52) . Interestingly, the adenosine receptor antagonist caffeine can cause OAB, and caffeine ingestion leads to OAB, increased void frequency, and reduced volume per void (53, 54) , suggesting an important role of the A2b receptor in regulating human bladder activity. Our findings in P2Y 12 -or A2b-deleted mice bladders are consistent with these reports in human urological studies, suggesting a clear mechanism for OAB in human patients and indicating that both P2Y 12 and A2b are logical and appealing targets for treating human bladder disorders. Our pharmacological calcium imaging studies in primary cultured human BSM further support this claim ( Figure 5 ). A2b receptor agonist Bay 60-6583 was proven to be potent in modulating in vivo mouse bladder function following i.p. injection ( Figure 7) . In addition, A2b receptor antagonist PSB1115 can reverse P2Y 12 -KO mouse in vivo bladder function, and P2Y 12 receptor antagonist Ticagrelor can reverse A2b-KO mouse in vivo bladder function by single-dose injection (Figure 7) . We predict these FDA-approved drugs, as well as currently unapproved drugs, are candidates that have great potential to readily translate into effective therapeutics for human patients with LUTS.
Methods
Reagents. Unless otherwise specified, all chemicals were obtained from MilliporeSigma and were of reagent grade or better. Agonists and antagonists, including α,β-Methyleneadenosine 5′-triphosphate trisodium (α,β-meATP), NECA, CGS21680, Bay 60-6583, Forskolin, and NKH 477 were all purchased from R&D Systems. Adenosine 5′-(β-thio)-diphosphate lithium salt (ADPβS) was purchased from Jena Bioscience. Fluo-4 AM, Pluronic F127, and X-gal were purchased from Invitrogen.
Animals. Male and female C57BL/6J mice (Jackson Laboratory), P2Y 12 -/-mice (55) in C57BL/6J background (provided by T.K. Gartner, University of Tennessee, Memphis, Tennessee, USA), and A2b -/-mice (56) in C57BL/6J background (a gift from K. Ravid, Boston University, Boston, Massachusetts, USA) (aged 12-16 weeks) were used. All experiments and groups were performed under matching conditions for age and sex. Only male or female mice were used in some experiments (see below). If not specified, both male and female mice were used. Mice were euthanized by 100% CO 2 inhalation from a gas cylinder into a plexiglass chamber. 12 and A2b signaling plays a key role in regulating bladder smooth muscle cell function and overall bladder activity. P2Y 12 and A2b signaling oppositely modulate downstream AC-cAMP cascade and thus intracellular calcium signaling, which specifically regulates bladder smooth muscle (BSM) purinergic contractility. Regulation of this signaling is important for the status of BSM contraction and relaxation. When A2b signaling dominates as shown in P2Y 12 -KO bladder, the relaxation activity will be dominant, resulting in increased bladder capacity and reduced voiding frequency. Conversely, when P2Y 12 signaling dominates as shown in A2b-KO bladder, the contracting activity will be dominant, resulting in decreased bladder capacity and increased voiding frequency.
Myography. Bladders from male wild-type, P2y 12 -/-
, and A2b -/-mice were pinned on a small Sylgard block and bladder mucosa was dissected away carefully. BSM strips were then cut longitudinally (2-3 mm wide and 5-7 mm long) and mounted in an SI-MB4 tissue bath system (World Precision Instruments). Force sensors were connected to a TBM 4M transbridge and the signal amplified by Powerlab and monitored through Chart software. Contraction force was monitored dynamically with a sampling rate of 2000/s. BSM strips were gently prestretched to get optimized force and equilibrated for at least 1 hour before any experiments. All experiments were conducted at 37°C in physiological saline solution (PSS in mM: Na, 136.9; K, 5.9; Ca, 2.5; Mg, 1.2; Cl, 133.6; HCO 3 , 15.5; H 2 PO 4 , 1.2; glucose, 11.5; pH 7.4), with continuous bubbling of 95% O 2 and 5% CO 2 . Data are analyzed statistically and BSM strip numbers are indicated as n.
EFS. EFS was carried out by a Grass S48 field stimulator (Grass Technologies) using standard protocols previously described (57) .
Spontaneous VSA. VSAs were performed as described previously (58) (59) (60) . Individual mice were gently placed in a standard polycarbonate mouse cage with Blicks Cosmos Blotting Paper (catalog 10422-1005) placed in the bottom, for 4 hours. Mice were given standard dry mouse chow for the duration of the assay. Water was withheld because of problems created by water dripping onto the filter paper. After 4 hours, the mice were returned to their home cages and the filter paper was allowed to dry. Filters were photographed under ultraviolet light at 365 nm in a UVP Chromato-Vue C-75 system (UVP) that incorporates an onboard Canon digital single lens reflex camera (EOS Rebel T3 -12 megapixels). Overlapping voiding spots were visually examined and manually separated by outlining and copying, then pasting to a nearby empty space in Fiji software (http://fiji.sc/wiki/index.php/Fiji). Images were analyzed by UrineQuant software developed by us in collaboration with the Harvard Imaging and Data Core. The results table, which contains the area of each voiding spot and total number of spots, were imported into Excel software for further statistical processing. A volume/area standard curve on this paper determined that 1 mm 2 is equal to 0.283 μL urine. Voiding spots that have an area ≥80 mm 2 are considered to be PVSs (59, 60) . CMG. CMG was performed as described previously and only female mice were used in this experiment (58, 59 ). Mice were anesthetized by subcutaneous injection of urethane (1.4 g/kg). Once the pedal reflex was absent, a 1-cm midline abdominal incision was performed and a flame-flanged PE50 tubing was implanted through the dome of the bladder, which was secured in place with an 8-0 polypropylene surgical suture. The mouse was placed into a restrainer and the catheter was connected to a pressure transducer (and syringe pump by side arm) coupled to data acquisition devices (WPI Transbridge and AD Instruments Powerlab 4/35) and computerized recording system (AD Instruments LabChart software). Acquired data are analyzed and voiding interval, basal pressure, threshold pressure, changes of peak pressure, bladder compliance, and voiding interval are presented.
Mouse primary cultured BSM cell. Bladders from 4-week-old mice were retrieved aseptically. Bladder was cut into small pieces and digested in 1% collagenase (Gibco) at 37°C for 1 hour on a shaker. Digested cells were centrifuged down and resuspended in fresh DMEM medium with 10% FBS. The cells were seeded in a flask for 2 hours in 37°C, then transported to another new flask to discard the rapid adherent fibroblasts. Smooth muscle cells were ready for experiment after 4 to 5 days growth.
Human primary cultured BSM cell. Normal human BSM cell (catalog FC-0043) was purchased from LifeLine Cell Technology and cultured in VascuLife SMC culture medium (catalog LL-0014) with 5% FBS, 10 mM L-glutamine, 30 μg/mL ascorbic acid, and 5 ng/mL recombinant human EGF and FGF basic.
Calcium imaging. Primary cultured BSM cells seeded onto glass coverslips for 2 days were ready for calcium imaging (61) . The cells were loaded with calcium sensitive dye FLUO4-AM (10 μM) and Pluronic F-127 (2.5 μg/mL) in the dark for 60 minutes. [Ca 2+ ] i was measured by exciting the cells at 495 nm light emitted from Lambda LS light source (Sutter Instrument). Images were digitized and analyzed using MetaFluor Imaging Software (Molecular Devices). The data were presented as fluorescence intensity. Drug application was regulated by VC-6 channel valve controller (Warner Instruments) and Peri-Star perfusion system (WPI).
RT-PCR and quantitative RT-PCR. Mouse bladders (wild type, P2Y 12 -/-
, and A2b -/-) were lysed for total RNA extraction by RNeasy Mini Kit (Qiagen). First-strand cDNA was synthesized from 1 μg total RNA using a SuperScript III First-Strand Synthesis System (Invitrogen). RT-PCR for gene detection and genotyping analysis was performed with Bio-Rad T100 Thermal Cycler. For quantitative RT-PCR, SYBR Green PCR Mix kits and a 7300 real-time PCR system (Applied Biosystems) was applied. SDHA (succinate dehydrogenase complex, subunit A) was used as an internal control. Each sample was analyzed triplicated. Primer details are provided in supplemental materials.
